FEATURED ARTICLES

• Scientific Data Is Not AI‑Ready By Default

  Convert siloed laboratory data into trusted, AI-ready assets. Learn to enforce data integrity principles at the point of origin to streamline analytics and reduce GxP compliance risks.

• Pharmaceutical Technology Transfer Steps
• CMC (Chemistry, Manufacturing and Controls) Management
• Glove Integrity Testing: Changes In EU GMP Annex 1
• The Alternative Solution To Comply With The New GMP Annex 1

WHITE PAPERS & CASE STUDIES

• Evaluation Of Novel Process Indicators For Hydrogen Peroxide Decontamination

  Immediate, quantifiable verification replaces seven-day incubation periods. Discover how enzyme-based indicators optimize hydrogen peroxide decontamination.

• Developing A Method To Assess Product And Personnel Safety In vH2O2 Decontamination Cycles

  Discover how ultra-sensitive spectroscopy transforms decontamination validation, revealing hidden efficiencies that safely cut facility downtime while ensuring absolute safety.

• Context-First Data For Trustworthy AI In Biopharma

  Bridge the gap between AI experimentation and enterprise value. Learn how capturing structured, semantically rich data at the point of origin builds regulator-credible AI pipelines.

• Top Questions Before You Buy A Hazardous Pharmacy Compounding Isolator

  Move beyond brochure specifications for hazardous compounding. Learn the critical airflow, structural, and pressure requirements needed to ensure long-term facility safety.

• Where Speed Meets Complexity In Bioprocess Development

  Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

• Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)

  ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.